Share Price and Basic Stock Data
Last Updated: December 12, 2025, 7:00 pm
| PEG Ratio | 6.68 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Wockhardt Ltd, a significant player in the Indian pharmaceuticals sector, has recently reported a notable market capitalization of ₹22,099 Cr, with its stock trading at ₹1,360. While the company has a history of fluctuating revenues, recent quarterly trends indicate some recovery. For instance, sales in the June 2023 quarter stood at ₹644 Cr and increased to ₹753 Cr by September 2023. This upward trajectory, however, is juxtaposed against a backdrop of historical underperformance, with annual revenues dropping from ₹4,830 Cr in March 2014 to ₹2,651 Cr in March 2023. The trailing twelve-month (TTM) revenue remains stagnated at ₹3,011 Cr, reflecting the ongoing struggle to regain pre-pandemic levels. This inconsistency in revenue generation raises questions about Wockhardt’s market positioning and strategic direction in an increasingly competitive landscape.
Profitability and Efficiency Metrics
Wockhardt’s profitability metrics paint a rather concerning picture. The reported net profit for March 2025 was a loss of ₹57 Cr, following a trend of negative earnings over the previous years. The operating profit margin (OPM) has shown some improvement, rising to 13% for the year ending March 2025, up from a mere 4% in March 2023. Despite this improvement, the company continues to face challenges with a low return on equity (ROE) of just 1.22% and a return on capital employed (ROCE) of 3.90%. These figures suggest that Wockhardt is struggling to translate its capital into profitable growth effectively. Coupled with a high price-to-earnings (P/E) ratio of 403, investors might find the current valuation stretched, especially given the persistent net losses and inconsistent profitability.
Balance Sheet Strength and Financial Ratios
Analyzing Wockhardt’s balance sheet reveals a mixed scenario. The company holds ₹4,486 Cr in reserves against total borrowings of ₹2,456 Cr, which indicates a reasonable buffer against its debts. The current ratio has improved to 1.26, suggesting a comfortable liquidity position. However, the interest coverage ratio (ICR) of 1.79 raises concerns, as it indicates that Wockhardt is barely able to meet its interest obligations. Additionally, the cash conversion cycle (CCC) of 123 days reflects inefficiencies in working capital management, which can strain cash flow further. Although the company has a manageable debt level relative to its equity, the overall financial ratios suggest a cautious approach to investments might be prudent, especially in light of the company’s ongoing profitability challenges.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Wockhardt indicates a significant presence of institutional investors, with foreign institutional investors (FIIs) holding 7.10% and domestic institutional investors (DIIs) at 11%. However, promoter holdings have seen a steady decline, dropping from 60.36% in December 2022 to 49.09% by March 2025. This reduction could signal waning confidence among the promoters, which often raises red flags for retail investors. The total number of shareholders has also decreased, from 1,84,908 in December 2022 to 1,37,946 in March 2025, suggesting that retail interest may be waning. This trend might reflect broader concerns about the company’s strategic direction and operational efficiency, potentially impacting future investment decisions.
Outlook, Risks, and Final Insight
The outlook for Wockhardt appears to be clouded with uncertainty. While there are signs of revenue recovery, the persistent net losses and declining profitability metrics pose significant risks. The company’s reliance on high debt levels, coupled with a stretched valuation, could deter potential investors. Moreover, the declining promoter stake might further impact market sentiment adversely. Investors need to be cautious, weighing the potential for recovery against the backdrop of operational inefficiencies and financial instability. Wockhardt’s ability to navigate these challenges will be crucial for restoring investor confidence and improving its market position. As such, it may be advisable for investors to closely monitor the company’s strategic initiatives and quarterly results before making significant investment commitments.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 237/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,250 Cr. | 390 | 479/192 | 88.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.1 | 31.0/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,469.84 Cr | 1,156.03 | 52.01 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 595 | 679 | 699 | 678 | 644 | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 |
| Expenses | 611 | 636 | 654 | 675 | 628 | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 |
| Operating Profit | -16 | 43 | 45 | 3 | 16 | 72 | 37 | -59 | 91 | 110 | 128 | 64 | 72 |
| OPM % | -3% | 6% | 6% | 0% | 2% | 10% | 5% | -8% | 12% | 14% | 18% | 9% | 10% |
| Other Income | 57 | -138 | -1 | -64 | 0 | 24 | 8 | 10 | 30 | 9 | 8 | 15 | -77 |
| Interest | 73 | 70 | 83 | 76 | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 |
| Depreciation | 64 | 65 | 66 | 56 | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 |
| Profit before tax | -96 | -230 | -105 | -193 | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 |
| Tax % | -22% | -10% | -3% | 23% | 15% | 109% | -1% | -2% | 167% | 78% | 5% | 105% | -1% |
| Net Profit | -75 | -207 | -102 | -237 | -136 | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 |
| EPS in Rs | -4.65 | -13.12 | -6.66 | -14.44 | -9.30 | -5.34 | -5.76 | -11.02 | -0.91 | -1.43 | 0.86 | -1.54 | -5.54 |
Last Updated: August 20, 2025, 1:10 am
Below is a detailed analysis of the quarterly data for Wockhardt Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 738.00 Cr.. The value appears to be declining and may need further review. It has decreased from 743.00 Cr. (Mar 2025) to 738.00 Cr., marking a decrease of 5.00 Cr..
- For Expenses, as of Jun 2025, the value is 666.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 679.00 Cr. (Mar 2025) to 666.00 Cr., marking a decrease of 13.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 72.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 72.00 Cr., marking an increase of 8.00 Cr..
- For OPM %, as of Jun 2025, the value is 10.00%. The value appears strong and on an upward trend. It has increased from 9.00% (Mar 2025) to 10.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is -77.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Mar 2025) to -77.00 Cr., marking a decrease of 92.00 Cr..
- For Interest, as of Jun 2025, the value is 48.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 48.00 Cr..
- For Depreciation, as of Jun 2025, the value is 56.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 53.00 Cr. (Mar 2025) to 56.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -109.00 Cr.. The value appears to be declining and may need further review. It has decreased from -22.00 Cr. (Mar 2025) to -109.00 Cr., marking a decrease of 87.00 Cr..
- For Tax %, as of Jun 2025, the value is -1.00%. The value appears to be improving (decreasing) as expected. It has decreased from 105.00% (Mar 2025) to -1.00%, marking a decrease of 106.00%.
- For Net Profit, as of Jun 2025, the value is -108.00 Cr.. The value appears to be declining and may need further review. It has decreased from -45.00 Cr. (Mar 2025) to -108.00 Cr., marking a decrease of 63.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -5.54. The value appears to be declining and may need further review. It has decreased from -1.54 (Mar 2025) to -5.54, marking a decrease of 4.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,830 | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,011 |
| Expenses | 3,805 | 3,772 | 3,959 | 4,002 | 3,935 | 3,604 | 2,725 | 2,771 | 2,932 | 2,550 | 2,707 | 2,619 | 2,637 |
| Operating Profit | 1,026 | 709 | 494 | 13 | 2 | -38 | 119 | -63 | 298 | 101 | 91 | 393 | 374 |
| OPM % | 21% | 16% | 11% | 0% | 0% | -1% | 4% | -2% | 9% | 4% | 3% | 13% | 12% |
| Other Income | 88 | 67 | 66 | 114 | -238 | 116 | 133 | 975 | -163 | -172 | 17 | 62 | -45 |
| Interest | 83 | 55 | 129 | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 254 | 229 |
| Depreciation | 140 | 145 | 142 | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 223 | 217 | 219 |
| Profit before tax | 891 | 575 | 289 | -247 | -641 | -351 | -247 | 417 | -411 | -624 | -420 | -16 | -119 |
| Tax % | 5% | 28% | 13% | -9% | 4% | -38% | -82% | -65% | -32% | -0% | 12% | 256% | |
| Net Profit | 843 | 413 | 252 | -226 | -667 | -217 | -43 | 689 | -279 | -621 | -472 | -57 | -149 |
| EPS in Rs | 58.91 | 28.30 | 17.45 | -13.62 | -42.30 | -13.52 | -4.81 | 47.64 | -16.94 | -38.80 | -30.18 | -2.89 | -7.65 |
| Dividend Payout % | 13% | 54% | 0% | -56% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -51.01% | -38.98% | -189.68% | -195.13% | 67.47% | 80.18% | 1702.33% | -140.49% | -122.58% | 23.99% | 87.92% |
| Change in YoY Net Profit Growth (%) | 0.00% | 12.03% | -150.70% | -5.45% | 262.60% | 12.72% | 1622.14% | -1842.82% | 17.91% | 146.57% | 63.93% |
Wockhardt Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 1% |
| 3 Years: | -2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 15% |
| TTM: | 85% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 40% |
| 3 Years: | 79% |
| 1 Year: | 36% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 0% |
| 3 Years: | -7% |
| Last Year: | -1% |
Last Updated: September 5, 2025, 1:56 pm
Balance Sheet
Last Updated: December 10, 2025, 3:40 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 77 | 81 | 81 |
| Reserves | 3,228 | 3,362 | 3,720 | 3,281 | 2,797 | 2,619 | 2,616 | 3,321 | 3,777 | 3,282 | 3,282 | 4,272 | 4,486 |
| Borrowings | 2,205 | 2,309 | 2,677 | 4,160 | 3,748 | 3,375 | 3,582 | 2,673 | 2,198 | 2,184 | 2,356 | 2,021 | 2,456 |
| Other Liabilities | 1,134 | 1,213 | 1,622 | 1,486 | 1,528 | 1,764 | 1,894 | 1,695 | 2,168 | 2,113 | 1,899 | 1,726 | 1,510 |
| Total Liabilities | 6,622 | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,744 | 8,215 | 7,651 | 7,614 | 8,100 | 8,533 |
| Fixed Assets | 2,295 | 2,123 | 2,809 | 2,773 | 2,888 | 3,058 | 3,502 | 3,343 | 3,462 | 3,042 | 2,881 | 2,736 | 4,396 |
| CWIP | 708 | 1,007 | 1,036 | 1,244 | 1,433 | 1,445 | 1,585 | 1,379 | 1,342 | 1,539 | 1,722 | 2,033 | 583 |
| Investments | 577 | 341 | 0 | 563 | 214 | 0 | 0 | 0 | 0 | 0 | 0 | 422 | 696 |
| Other Assets | 3,043 | 3,468 | 4,228 | 4,403 | 3,593 | 3,309 | 3,060 | 3,022 | 3,411 | 3,070 | 3,011 | 2,909 | 2,858 |
| Total Assets | 6,622 | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,744 | 8,215 | 7,651 | 7,614 | 8,100 | 8,533 |
Below is a detailed analysis of the balance sheet data for Wockhardt Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 81.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 81.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,486.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,272.00 Cr. (Mar 2025) to 4,486.00 Cr., marking an increase of 214.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,456.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,021.00 Cr. (Mar 2025) to 2,456.00 Cr., marking an increase of 435.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,510.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,726.00 Cr. (Mar 2025) to 1,510.00 Cr., marking a decrease of 216.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8,533.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8,100.00 Cr. (Mar 2025) to 8,533.00 Cr., marking an increase of 433.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,396.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,736.00 Cr. (Mar 2025) to 4,396.00 Cr., marking an increase of 1,660.00 Cr..
- For CWIP, as of Sep 2025, the value is 583.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,033.00 Cr. (Mar 2025) to 583.00 Cr., marking a decrease of 1,450.00 Cr..
- For Investments, as of Sep 2025, the value is 696.00 Cr.. The value appears strong and on an upward trend. It has increased from 422.00 Cr. (Mar 2025) to 696.00 Cr., marking an increase of 274.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,858.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,909.00 Cr. (Mar 2025) to 2,858.00 Cr., marking a decrease of 51.00 Cr..
- For Total Assets, as of Sep 2025, the value is 8,533.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,100.00 Cr. (Mar 2025) to 8,533.00 Cr., marking an increase of 433.00 Cr..
Notably, the Reserves (4,486.00 Cr.) exceed the Borrowings (2,456.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.00 | 707.00 | 492.00 | 9.00 | -1.00 | -41.00 | 116.00 | -65.00 | 296.00 | 99.00 | 89.00 | 391.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 36 | 60 | 91 | 94 | 89 | 130 | 159 | 124 | 104 | 110 | 81 | 80 |
| Inventory Days | 201 | 250 | 249 | 243 | 174 | 183 | 209 | 256 | 222 | 216 | 201 | 234 |
| Days Payable | 113 | 136 | 144 | 117 | 122 | 187 | 272 | 223 | 265 | 285 | 240 | 191 |
| Cash Conversion Cycle | 124 | 175 | 196 | 220 | 141 | 126 | 97 | 157 | 60 | 41 | 41 | 123 |
| Working Capital Days | -7 | 14 | 52 | 36 | -56 | -51 | -171 | -133 | -116 | -186 | -163 | -23 |
| ROCE % | 18% | 10% | 7% | -1% | -1% | -1% | 0% | 12% | 1% | -0% | -1% | 4% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Tata Small Cap Fund | 1,929,375 | 2.1 | 247.25 | N/A | N/A | N/A |
| HSBC Small Cap Fund | 1,325,150 | 1.03 | 169.82 | N/A | N/A | N/A |
| Tata Large & Mid Cap Fund | 978,826 | 1.42 | 125.44 | N/A | N/A | N/A |
| ICICI Prudential ELSS Tax Saver Fund | 830,222 | 0.72 | 106.39 | N/A | N/A | N/A |
| HDFC Multi Cap Fund | 588,567 | 0.38 | 75.42 | N/A | N/A | N/A |
| Invesco India Smallcap Fund | 575,064 | 0.85 | 73.69 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 572,354 | 0.42 | 73.35 | N/A | N/A | N/A |
| Invesco India Contra Fund | 466,063 | 0.3 | 59.73 | N/A | N/A | N/A |
| ICICI Prudential Equity & Debt Fund | 359,543 | 0.1 | 46.08 | N/A | N/A | N/A |
| HSBC Flexi Cap Fund | 334,700 | 0.81 | 42.89 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | -3.02 | -32.05 | -38.79 | -20.24 | 61.95 |
| Diluted EPS (Rs.) | -3.02 | -32.05 | -38.79 | -20.24 | 61.68 |
| Cash EPS (Rs.) | 9.88 | -16.17 | -25.69 | -2.22 | 84.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 268.70 | 237.79 | 254.31 | 291.81 | 339.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 268.70 | 237.79 | 254.31 | 291.81 | 339.43 |
| Revenue From Operations / Share (Rs.) | 185.93 | 181.69 | 184.10 | 224.31 | 244.48 |
| PBDIT / Share (Rs.) | 28.09 | 7.92 | 15.49 | 22.08 | 6.25 |
| PBIT / Share (Rs.) | 14.69 | -6.56 | -1.94 | 4.93 | -15.96 |
| PBT / Share (Rs.) | -0.98 | -27.27 | -43.33 | -28.54 | 81.42 |
| Net Profit / Share (Rs.) | -3.52 | -30.65 | -43.13 | -19.38 | 62.16 |
| NP After MI And SOA / Share (Rs.) | -2.90 | -30.06 | -38.82 | -16.94 | 61.93 |
| PBDIT Margin (%) | 15.10 | 4.36 | 8.41 | 9.84 | 2.55 |
| PBIT Margin (%) | 7.90 | -3.60 | -1.05 | 2.19 | -6.52 |
| PBT Margin (%) | -0.53 | -15.01 | -23.53 | -12.72 | 33.30 |
| Net Profit Margin (%) | -1.89 | -16.86 | -23.42 | -8.63 | 25.42 |
| NP After MI And SOA Margin (%) | -1.56 | -16.54 | -21.08 | -7.55 | 25.33 |
| Return on Networth / Equity (%) | -1.07 | -13.78 | -16.66 | -6.33 | 20.31 |
| Return on Capital Employeed (%) | 3.90 | -2.07 | -0.65 | 1.40 | -3.79 |
| Return On Assets (%) | -0.57 | -6.05 | -7.27 | -2.96 | 8.82 |
| Long Term Debt / Equity (X) | 0.27 | 0.26 | 0.06 | 0.09 | 0.14 |
| Total Debt / Equity (X) | 0.42 | 0.62 | 0.56 | 0.48 | 0.46 |
| Asset Turnover Ratio (%) | 0.38 | 0.36 | 0.33 | 0.20 | 0.15 |
| Current Ratio (X) | 1.26 | 0.78 | 0.64 | 0.80 | 0.77 |
| Quick Ratio (X) | 0.90 | 0.55 | 0.45 | 0.56 | 0.52 |
| Inventory Turnover Ratio (X) | 4.41 | 0.95 | 0.72 | 0.47 | 0.48 |
| Interest Coverage Ratio (X) | 1.79 | 0.40 | 0.73 | 1.06 | 0.27 |
| Interest Coverage Ratio (Post Tax) (X) | 0.77 | -0.50 | -0.08 | 0.67 | 0.38 |
| Enterprise Value (Cr.) | 25036.75 | 10872.67 | 4287.88 | 5607.72 | 6250.83 |
| EV / Net Operating Revenue (X) | 8.31 | 3.89 | 1.62 | 1.74 | 2.31 |
| EV / EBITDA (X) | 55.03 | 89.12 | 19.23 | 17.63 | 90.28 |
| MarketCap / Net Operating Revenue (X) | 7.66 | 3.21 | 0.83 | 1.18 | 1.69 |
| Price / BV (X) | 5.30 | 2.68 | 0.66 | 0.98 | 1.36 |
| Price / Net Operating Revenue (X) | 7.66 | 3.21 | 0.83 | 1.18 | 1.69 |
| EarningsYield | 0.00 | -0.05 | -0.25 | -0.06 | 0.14 |
After reviewing the key financial ratios for Wockhardt Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 5. It has increased from -32.05 (Mar 24) to -3.02, marking an increase of 29.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 5. It has increased from -32.05 (Mar 24) to -3.02, marking an increase of 29.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.88. This value is within the healthy range. It has increased from -16.17 (Mar 24) to 9.88, marking an increase of 26.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 268.70. It has increased from 237.79 (Mar 24) to 268.70, marking an increase of 30.91.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 268.70. It has increased from 237.79 (Mar 24) to 268.70, marking an increase of 30.91.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 185.93. It has increased from 181.69 (Mar 24) to 185.93, marking an increase of 4.24.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.09. This value is within the healthy range. It has increased from 7.92 (Mar 24) to 28.09, marking an increase of 20.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 14.69. This value is within the healthy range. It has increased from -6.56 (Mar 24) to 14.69, marking an increase of 21.25.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.98. This value is below the healthy minimum of 0. It has increased from -27.27 (Mar 24) to -0.98, marking an increase of 26.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -3.52. This value is below the healthy minimum of 2. It has increased from -30.65 (Mar 24) to -3.52, marking an increase of 27.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.90. This value is below the healthy minimum of 2. It has increased from -30.06 (Mar 24) to -2.90, marking an increase of 27.16.
- For PBDIT Margin (%), as of Mar 25, the value is 15.10. This value is within the healthy range. It has increased from 4.36 (Mar 24) to 15.10, marking an increase of 10.74.
- For PBIT Margin (%), as of Mar 25, the value is 7.90. This value is below the healthy minimum of 10. It has increased from -3.60 (Mar 24) to 7.90, marking an increase of 11.50.
- For PBT Margin (%), as of Mar 25, the value is -0.53. This value is below the healthy minimum of 10. It has increased from -15.01 (Mar 24) to -0.53, marking an increase of 14.48.
- For Net Profit Margin (%), as of Mar 25, the value is -1.89. This value is below the healthy minimum of 5. It has increased from -16.86 (Mar 24) to -1.89, marking an increase of 14.97.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.56. This value is below the healthy minimum of 8. It has increased from -16.54 (Mar 24) to -1.56, marking an increase of 14.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.07. This value is below the healthy minimum of 15. It has increased from -13.78 (Mar 24) to -1.07, marking an increase of 12.71.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.90. This value is below the healthy minimum of 10. It has increased from -2.07 (Mar 24) to 3.90, marking an increase of 5.97.
- For Return On Assets (%), as of Mar 25, the value is -0.57. This value is below the healthy minimum of 5. It has increased from -6.05 (Mar 24) to -0.57, marking an increase of 5.48.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has increased from 0.26 (Mar 24) to 0.27, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.42, marking a decrease of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.38. It has increased from 0.36 (Mar 24) to 0.38, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.26. This value is below the healthy minimum of 1.5. It has increased from 0.78 (Mar 24) to 1.26, marking an increase of 0.48.
- For Quick Ratio (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.55 (Mar 24) to 0.90, marking an increase of 0.35.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.41. This value is within the healthy range. It has increased from 0.95 (Mar 24) to 4.41, marking an increase of 3.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.79. This value is below the healthy minimum of 3. It has increased from 0.40 (Mar 24) to 1.79, marking an increase of 1.39.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 3. It has increased from -0.50 (Mar 24) to 0.77, marking an increase of 1.27.
- For Enterprise Value (Cr.), as of Mar 25, the value is 25,036.75. It has increased from 10,872.67 (Mar 24) to 25,036.75, marking an increase of 14,164.08.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.31. This value exceeds the healthy maximum of 3. It has increased from 3.89 (Mar 24) to 8.31, marking an increase of 4.42.
- For EV / EBITDA (X), as of Mar 25, the value is 55.03. This value exceeds the healthy maximum of 15. It has decreased from 89.12 (Mar 24) to 55.03, marking a decrease of 34.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.66. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 24) to 7.66, marking an increase of 4.45.
- For Price / BV (X), as of Mar 25, the value is 5.30. This value exceeds the healthy maximum of 3. It has increased from 2.68 (Mar 24) to 5.30, marking an increase of 2.62.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.66. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 24) to 7.66, marking an increase of 4.45.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.00, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Wockhardt Ltd:
- Net Profit Margin: -1.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.9% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.07% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.77
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.9
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 397 (Industry average Stock P/E: 42.78)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -1.89%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | D-4, MIDC, Aurangabad Maharashtra 431006 | investorrelations@wockhardt.com http://www.wockhardt.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Habil Khorakiwala | Founder Chairman |
| Dr. Murtaza Khorakiwala | Managing Director |
| Dr. Huzaifa Khorakiwala | Executive Director |
| Ms. Zahabiya Khorakiwala | Non Executive Director |
| Mrs. Tasneem Mehta | Independent Director |
| Mr. Vinesh Kumar Jairath | Independent Director |
| Mr. Akhilesh Gupta | Independent Director |
| Ms. Amelia Fernandes | Independent Director |
| Mr. Ahmad Javed | Independent Director |
FAQ
What is the intrinsic value of Wockhardt Ltd?
Wockhardt Ltd's intrinsic value (as of 13 December 2025) is 1110.57 which is 17.18% lower the current market price of 1,341.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 21,802 Cr. market cap, FY2025-2026 high/low of 1,870/1,110, reserves of ₹4,486 Cr, and liabilities of 8,533 Cr.
What is the Market Cap of Wockhardt Ltd?
The Market Cap of Wockhardt Ltd is 21,802 Cr..
What is the current Stock Price of Wockhardt Ltd as on 13 December 2025?
The current stock price of Wockhardt Ltd as on 13 December 2025 is 1,341.
What is the High / Low of Wockhardt Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Wockhardt Ltd stocks is 1,870/1,110.
What is the Stock P/E of Wockhardt Ltd?
The Stock P/E of Wockhardt Ltd is 397.
What is the Book Value of Wockhardt Ltd?
The Book Value of Wockhardt Ltd is 281.
What is the Dividend Yield of Wockhardt Ltd?
The Dividend Yield of Wockhardt Ltd is 0.00 %.
What is the ROCE of Wockhardt Ltd?
The ROCE of Wockhardt Ltd is 3.75 %.
What is the ROE of Wockhardt Ltd?
The ROE of Wockhardt Ltd is 1.22 %.
What is the Face Value of Wockhardt Ltd?
The Face Value of Wockhardt Ltd is 5.00.